Kintossou Ambroise Kouame, Villar Stephanie, Kozlakidis Zisis
Biobank, Pasteur Institute of Côte d'Ivoire, Abidjan, Côte d'Ivoire.
International Agency for Research on Cancer, World Health Organization, 69372 Lyon CEDEX 08, France.
Biosaf Health. 2023 Apr;5(2):108-111. doi: 10.1016/j.bsheal.2023.03.001.
The vulnerability of healthcare and laboratory to potential infection by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus has thus far been analyzed through the lens of the acute phase of the pandemic, including remote-based work, as well as emergency settings that are different from routine healthcare operations. However, as lockdowns ease and activities return to an identifiable pre-pandemic routine, the safety considerations also require to shift accordingly. As laboratory workers are likely to continue being exposed to unidentified SARS-CoV-2 positive samples through routine blood collection and processing operations, coronavirus disease 2019 (COVID-19) might have to be re-considered as an occupational disease within this context. Additionally, as per many such occupational diseases, a surveillance system is implemented for the medium- and long-term. This manuscript presents the views on the possible surveillance scenarios for laboratory staff, viewed from an immunological and biosafety perspective.
到目前为止,医疗保健机构和实验室对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)病毒潜在感染的脆弱性,一直是从大流行急性期的角度进行分析的,包括远程工作以及与常规医疗保健操作不同的紧急情况。然而,随着封锁措施的放松,活动恢复到可识别的疫情前常规状态,安全考虑也需要相应转变。由于实验室工作人员可能会通过常规血液采集和处理操作继续接触不明的SARS-CoV-2阳性样本,在这种情况下,2019冠状病毒病(COVID-19)可能不得不被重新视为一种职业病。此外,与许多此类职业病一样,需要实施中长期监测系统。本手稿从免疫学和生物安全角度,阐述了对实验室工作人员可能的监测方案的看法。